436 related articles for article (PubMed ID: 17851042)
1. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.
Perlick DA; Rosenheck RA; Kaczynski R; Bingham S; Collins J
Schizophr Res; 2008 Feb; 99(1-3):192-9. PubMed ID: 17851042
[TBL] [Abstract][Full Text] [Related]
2. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
[TBL] [Abstract][Full Text] [Related]
4. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
[TBL] [Abstract][Full Text] [Related]
5. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.
Lipkovich IA; Deberdt W; Csernansky JG; Sabbe B; Keefe RS; Kollack-Walker S
BMC Psychiatry; 2009 Jul; 9():44. PubMed ID: 19602273
[TBL] [Abstract][Full Text] [Related]
6. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
[TBL] [Abstract][Full Text] [Related]
7. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
[TBL] [Abstract][Full Text] [Related]
8. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
Tollefson GD; Andersen SW
J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
[TBL] [Abstract][Full Text] [Related]
9. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
10. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
[TBL] [Abstract][Full Text] [Related]
11. Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.
Frazier JA; Giuliano AJ; Johnson JL; Yakutis L; Youngstrom EA; Breiger D; Sikich L; Findling RL; McClellan J; Hamer RM; Vitiello B; Lieberman JA; Hooper SR
J Am Acad Child Adolesc Psychiatry; 2012 May; 51(5):496-505. PubMed ID: 22525956
[TBL] [Abstract][Full Text] [Related]
12. Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.
Poyurovsky M; Faragian S; Fuchs C; Pashinian A
Isr J Psychiatry Relat Sci; 2009; 46(3):213-20. PubMed ID: 20039523
[TBL] [Abstract][Full Text] [Related]
13. Relationship of cognition and psychopathology to functional impairment in schizophrenia.
Mohamed S; Rosenheck R; Swartz M; Stroup S; Lieberman JA; Keefe RS
Am J Psychiatry; 2008 Aug; 165(8):978-87. PubMed ID: 18450928
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
[TBL] [Abstract][Full Text] [Related]
16. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.
Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880
[TBL] [Abstract][Full Text] [Related]
17. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.
Krakowski MI; Czobor P; Nolan KA
J Clin Psychopharmacol; 2008 Oct; 28(5):485-93. PubMed ID: 18794642
[TBL] [Abstract][Full Text] [Related]
18. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
[TBL] [Abstract][Full Text] [Related]
19. Daily activities, cognition and community functioning in persons with schizophrenia.
Aubin G; Stip E; GĂ©linas I; Rainville C; Chapparo C
Schizophr Res; 2009 Feb; 107(2-3):313-8. PubMed ID: 18824328
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic drug effects on brain morphology in first-episode psychosis.
Lieberman JA; Tollefson GD; Charles C; Zipursky R; Sharma T; Kahn RS; Keefe RS; Green AI; Gur RE; McEvoy J; Perkins D; Hamer RM; Gu H; Tohen M;
Arch Gen Psychiatry; 2005 Apr; 62(4):361-70. PubMed ID: 15809403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]